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1. Introduction 
Hepatocellular carcinoma (HCC) most common primary liver cancers reported world wide. HCC occurs mainly 
in males and gender is an important risk factor [1]. There are another risk factor such as chronic liver inflammation 
due to hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.[2, 3]  There are  no satisfactory screening 
procedures for early detection for HCC is available, serum alpha fetoprotein (AFP) and ultrasound scan is commonly 
recommended [4].   AFP is a major serum glycoprotein comprised of 591 amino acids with a half-life of 5-7 days, 
which is synthesized by fetal liver cells, by yolk sac cells, and in trace amounts by the fetal gastrointestinal tract [5, 
6]. Reappearance of AFP in adult serum often signals pathologic conditions, particularly the presence of 
hepatocellular carcinomas (HCC) and germ cell tumors containing yolk sac cell elements [7, 8]. In 60-70% of 
patients with HCC high serum AFP has been reported, but there are other causes in which increased levels are seen, 
such as cirrhosis, lung cancer, biliary cancer, gastric cancer, pancreatic cancer, teratocarcinoma of the testis, 
spherocytosis and tyrosinemia [9]. Although AFP has certain limitation which compels to search for other prognostic 
marker, so we investigate the clinical value of serum interleukin-6(IL-6) in diagnosing primary hepatocellular 
carcinoma along with AFP. 
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays an important role in hematopoiesis, as well as in the 
differentiation and growth of a number of cells of different histologic origin, e.g. endothelial cells, keratinocytes, 
neuronal cells, osteoclasts, and osteoblasts [10]. Moreover, IL-6 induces the hepatic acute phase response by 
modulating the transcription of several liver-specific genes during inflammation [11].IL-6 may also regulate cell 
growth and act as a paracrine and autocrine growth factor in different malignancies [12]. Furthermore, serum IL-6 
levels are reportedly higher in patients with HCC than in those without [13]. 
Background: Hepatocellular carcinoma (HCC) is one of the important cancers 
worldwide and predominant in Asia and Africa. A number of evidence suggests a 
possible role of interleukin-6 (IL-6) and α-Fetoprotein (AFP) in the pathogenesis of 
hepatocellular carcinoma (HCC). 
Patients and methods: We studied both IL-6 and AFP in patients with HCC or in 
healthy controls. Serum IL-6, AFP was measured by enzyme linked immunosorbent 
assay and Chemiluminescent immunoassay respectively in 30 patients with primary 
hepatocellular carcinoma and 30 normal subjects 
Results:IL-6 and AFP was found in high levels in the serum of patients initially 
diagnosed with HCC (18±9.8), and (315.99±594.62) respectively compared with healthy 
subjects (4.29±2.10).and (3.13±1.27).A significant positive correlation was found 
between mean levels of IL- 6 & AFP in HCC (P < 0.05), Combination of IL-6 and AFP 
improved the sensitivity in diagnosing HCC or predicting future HCC development. 
Conclusions: IL-6 along with AFP could be considered a promising tumor marker for 
HCC. In particular, the diagnostic value of the test is significantly increased when 
combined with AFP. 
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In chronic hepatitis, IL-6, produced mainly by activated Kupffer cells, intensifies local inflammatory responses 
and induces compensatory hepatocyte proliferation, facilitating malignant transformation of hepatocytes [14]. Also, 
IL-6 induces the hepatic acute phase response by modulating the transcription of several liver specific genes during 
inflammation [15]. Moreover, Giannitrapani et al indicated that IL-6 could be more sensitive marker in identifying 
HCCs than AFP [16]. 
New biomarkers for earlier diagnosis of HCC with high sensitivity and identification of high risk groups are 
required. 
 
1.1. Patients and Methods 
Patients: The study involved 60 subjects who were divided into two groups. The control group consisted of 30 
healthy subjects (26 women and 14 men) with an average age of 55.38 years, who were from 30 to 70 years old; they 
also did not have family history of HCC and they were not medically treated. Rest 30 subjects were diagnosed with 
HCC. Detailed clinical history and examination were carried out and recorded in preformed Performa. The study 
conducted in the Department of Biochemistry in collaboration with the Department of Gastroenterology, during the 
period from Jan 2010 to March 2012. 
 Blood sampleswere collected from eighty patients who were attending to Indira Gandhi Institute of Medical 
Sciences Patna teaching hospital. Sera were separated and stored at -20 ºC until use. 
 
2. Methods 
AFP was performed by Chemiluminescent Immunoassay Beckman coulter Inc.IL-6 serum titers were evaluated 
in the peripheral blood of all the above patients; blood samples were taken from an antecubital vein of the forearm of 
each study subject, after overnight fasting; serum was centrifuged and then frozen at 24 
0
C for subsequent analysis. 
Serum IL-6 was titered using a commercial enzyme-linked immunosorbent assay kit (Human IL-6 Immunoassay, 
R&D Systems,  Minneapolis, MN) following the manufacturer’s instructions and the results were expressed as 
pg/ml. 
Statistical Analysis: The data of the study subjected to statistical analysis is expressed as mean ± SD. Statistical 
comparisons were performed by Student‘t’ test. 
 
3. Results 
Form 60 patients, 26 (65%) of them were women while only 14 (35%) of who were men. The mean age of the 
patients was 55.38 ± 10.05 (55.26 ± 7.93 for women and 54.85 ± 8.23 for men).  
The mean serum AFP level in case HCC was (315.99±594.62) and in control was (3.13±1.27).  The normal cut-off 
value is less than 5.0 ng/ml. It is interesting to note that a large number of patients, both males and females with 
elevated levels of AFP are basically diagnosed with HCV or HBV infections. 
Chronic hepatitis C patients had signiﬁcantly higher serum IL-6 levels than healthy controls (18±9.8) vs. (4.29±2.10) 
pg/ ml, p < 0.005) and the difference was similar in male and female. 
 
Table-1. Serum Alfa feto-protein and Interlukin level in different groups 
Groups AFP IL-6 
Control (N=30) 3.13±1.27 4.29±2.10 
HCC       (N=30) 315.99±594.62** 18±9.8*** 
                                           ***P<0.005,      **p<0.05 
 
4. Discussion 
AFP one of the serum glycoprotein that was discovered by Bergstrand and Czar [17]  in 1956 using paper for its 
electrophoretic separation from human fetoprotein in serum, and it was first described by Abelev, et al. [18] in 1960.  
The first quantitative serum assays for AFP were established by Ruoslahti and Seppälä [19]. Up to 11 AFP isoforms 
exist based on variations in the glycan terminal chain [20, 21]Taketa et al found AFP-L3 to be positive in about 35% 
of patients with HCC smaller than 2 cm, which may be present in serum up to 9 months before detection by imaging 
techniques [22]. More recently, isoelectric focusing has been investigated, which fractionates AFP into four variant 
bands, I-IV. AFP bands III and IV can be specific for HCC and help differentiate from AFP of cirrhosis or 
pregnancy [23] Chronic hepatitis or cirrhosis raise AFP in 20% and 50% of patients, respectively, and tend to 
fluctuate in parallel with underlying inflammatory activity [24]. The sensitivity of AFP is low renders it 
unsatisfactory for this purpose and compels to search for novel biomarkers for the detection of early HCC [25]. 
Many studies indicated a big role for IL-6 in the process of liver damage and carcinogenesis [26, 27]. Previous 
studies have confirmed that serum IL-6 level is increased in patients with established HCC.[28-33] However, since 
IL-6 levels were checked after the diagnosis of HCC, it is impossible to differentiate whether IL-6 production is the 
response to HCC, or IL-6 contributes to the development of HCC. In fact, IL-6 level decreases after surgical 
resection of HCC, and high IL-6 at the day of surgery is associated with prolonged hyperbilirubinemia after 
surgery.[34] 
It is well documented that AFP estimation remains along with IL-6 a useful test for clinicians, oncologists and 
physicians involved in the management of patients of HCC. 
 
5. Conclusion 
In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has 
moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC 
surveillance program. Combining the two markers can provide a new perspective in the diagnosis and prognosis of 
HCC. 
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